Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
Journal of Cardiovascular Pharmacology and Therapeutics|November 26, 2013
Evacetrapib at a supratherapeutic steady state concentration does not prolong QT in a thorough QT/QTc study in healthy participantsJeffrey G Suico, Stuart Friedrich, Kathryn A Krueger, et al.Journal of Cardiovascular Pharmacology and Therapeutics|March 5, 2015
A Multidose Study to Examine the Effect of Food on Evacetrapib Exposure at Steady StateDavid S Small, Wei Zhang, Jane Royalty, et al.European Journal of Clinical Pharmacology|February 10, 2016
Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapibDavid S Small, Wei Zhang, Jane Royalty, et al.Pharmacotherapy|June 11, 2016
Impact of Increased Gastric pH on the Pharmacokinetics of Evacetrapib in Healthy SubjectsDavid S Small, Jane Royalty, Ellen A Cannady, et al.The Journal of Pharmacy and Pharmacology|June 26, 2014
Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adultsJeffrey G Suico, Ming-Dauh Wang, Stuart Friedrich, et al.Journal of Clinical Pharmacology|November 28, 2017
Serum Lipid and Protein Changes in Healthy Dyslipidemic Subjects Given a Selective Inhibitor of p70 S6 Kinase-1Jennifer K Leohr, Debra Luffer-Atlas, M Jane Luo, et al.British Journal of Clinical Pharmacology|August 13, 2015
CYP-mediated drug-drug interactions with evacetrapib, an investigational CETP inhibitor: in vitro prediction and clinical outcomeEllen A Cannady, Jeffrey G Suico, Ming-Dauh Wang, et al.Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 10, 2020
Glucagon Administration by Nasal and Intramuscular Routes in Adults With Type 1 Diabetes During Insulin-Induced Hypoglycaemia: A Randomised, Open-Label, Crossover StudyJeffrey G Suico, Ulrike Hövelmann, Shuyu Zhang, et al.Pharmacology Research & Perspectives|October 31, 2015
Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitorsEllen A Cannady, Ming-Dauh Wang, Stuart Friedrich, et al.Clinical Chemistry|March 26, 2003
LOINC, a universal standard for identifying laboratory observations: a 5-year updateClement J McDonald, Stanley M Huff, Jeffrey G Suico, et al.Pageof 2